相关实验视频

Updated: Jun 25, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

针对雄激素受体信号的PROTACs:对于割抵抗性前列腺癌的潜在治疗剂

Yulu Zhang1, Annan Ming1, Junyan Wang2

  • 1Department of Urology, Qilu Hospital of Shandong University, Ji'nan, China; Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji'nan, China.

Pharmacological research
|May 30, 2024
PubMed
概括

新的PROTACs为治疗晚期前列腺癌提供了希望. 这种蛋白质溶解向奇美拉 (PROTAC) 技术降解了雄激素受体 (AR),克服了对目前转移性割耐性前列腺癌 (mCRPC) 治疗方法的耐药性.

关键词:
艾滋病病毒-110 (PubChem CID: 134414307);艾滋病病毒-766 (PubChem CID: 156504141);艾滋病病毒-110 (PubChem CID: 134414307);艾滋病病毒-766 (PubChem CID: 156504141);艾滋病病毒-766 (PubChem CID: 156504141);艾滋病病毒-766 (PubChem CID: 156504141);艾滋病病毒-110 (PubChem CID: 134414307);艾滋病病毒-766 (PubChem CID: 156504141);艾滋病病毒-766 (PubChem CID: 156504141);艾滋病病毒-110 (PubChem CID: 134414307);艾滋病病毒-766 (PubChem CID: 156504141);艾滋病病毒ARV-771 (PubChem CID: 1266-19980) 是一个在线的药物.AU-15330 (PubChem CID: 156168451) 是一个可以使用的代码.雄激素受体 (AR) 是一种BWA-522 (PubChem CID: 168679672) 这款产品的使用情况癌症治疗治疗 癌症治疗化抵抗性前列腺癌 (CRPC) 是一种癌症.目标药物是药物目标.EN300-72284 (PubChem CID: 28393863) 这是一个非常简单的数字.EN300-72284 (PubChem CID: 50988397) 标签: 电子书 电子书 电子书 电子书 电子书 电子书MS177 (PubChem CID: 139413605) 这是一本书.MTX-23 (PubChem CID: 154612215) 这款产品的使用情况蛋白质溶解向的木乃伊 (PROTAC) 的研究.

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167